Latest Recruitment News

TrivarX has completed recruitment of 60 patients in its US veteran-focused mental health trial, advancing validation of its novel single-lead ECG algorithm for depression screening. Positive interim results from 27 patients set the stage for full data release and commercial discussions.

Judo Capital Holdings Limited reported strong FY25 results with significant lending growth and profit increases, while expanding its SME banking footprint and advancing technology. The bank sets confident FY26 guidance amid strategic board changes.

Singular Health Group has advanced its US expansion through the deployment of 3DICOM™ licenses under a key contract with Provider Network Solutions, alongside appointing a new US commercial chief to drive growth.

Bapcor reports a 2.7% revenue decline in 1Q26 and outlines a comprehensive operational review and cost-saving plan, setting cautious guidance for FY26.

Actinogen Medical has fast-tracked recruitment in its XanaMIA Alzheimer’s trial, closing pTau biomarker screening early and increasing participant numbers, aiming for final results by mid Q4 2026.

PWR Holdings announces a pivotal leadership transition alongside the completion of its new global headquarters, reporting a transitional FY25 with mixed financial results but a confident outlook for FY26.

American Rare Earths reports key technical breakthroughs and strong funding progress at its Halleck Creek Rare Earths Project, positioning it as a vital domestic source for the US rare earths supply chain.

Queensland Brine Solutions has locked in a strategic 10-hectare site to develop its Queensland Brine Management Complex, aiming to transform waste brine from the coal seam gas industry into valuable green chemicals.

Anteris Technologies has secured its first European regulatory clearance to commence the global PARADIGM Trial for its DurAVR Transcatheter Heart Valve, marking a significant step toward worldwide commercialization.

Tryptamine Therapeutics has enrolled the first patient in its pioneering clinical trial testing TRP-8803, an IV-infused psilocin formulation, for Binge Eating Disorder. The study aims to evaluate safety and efficacy, potentially reshaping treatment options for millions.

PainChek Limited has secured its first US customer, Jewish Home Family, just days after receiving FDA De Novo clearance for its AI-powered pain assessment app, marking a significant step into the $100 million US aged care market.

Immutep Limited has confirmed 30 mg as the optimal biological dose for its immunotherapy efti, following FDA approval of Project Optimus requirements. This milestone paves the way for the US launch of its pivotal Phase III lung cancer trial.